Find a Product

Biologics Webinar Series

Accelerating biologics drug discovery

Learn how DiscoverX is leading the way in accelerating biologics drug discovery.  This webinar series addresses some of the important challenges associated with the identification and development of biologic therapeutics.
Webinars will continue to be added to this series, so please check back often.


Event Date ▼ Event Name PDF Link Webinar Link
October 9, 2019 Webinar: Establishing Qualified Bioassays for Checkpoint Receptors to Implement in QC Lot Release: Case Studies on PD-1 and SIRPα - 60 min.
Login to view Login to view
May 9, 2018 Webinar: Accelerate Biologics and Biosimilars Development: Case Studies Implementing Robust and Simple Potency Bioassays - 60 min.
Login to view Login to view
November 29, 2017 Webinar: Implementing ADCC assays in QC: When donor variability isn’t an option - 55 min.
Login to view Login to view
November 1, 2017 Webinar: How to Accelerate Your Biotherapeutic Development with Cell-Based Assay Services - 40 min.

What will be covered?

  • How PathHunter services save development time compared to in-house assays
  • Screening and profiling biologics with highly specific and sensitive assays that produce robust and reproducible results
  • Example data from marketed drugs, like Pembrolizumab and Nivolumab, using these cell-based assays
Login to view Login to view
June 27, 2017 Webinar: Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells - 55 min.

What will be covered?

  • Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
  • Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
  • Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells
Login to view Login to view
March 10, 2017 免疫チェックポイント阻害剤の評価に適切なセルベースアッセイ系のご紹介 - 60 min.

What will be covered?

  • 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
  • PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
  • 放射性同位体を使用しないADCC(抗体依存性細胞傷害)の評価系
Login to view Login to view